74896-30-3

Upstream product

• 5467-64-1 2-acetamidophenyl acetate 
• 6322-56-1 4'-hydroxy-3'-nitroacetophenone 
• 108-24-7 acetic anhydride 
• 54255-50-4 3-amino-4-hydroxyacetophenone 
• 75-36-5 acetyl chloride 
• 614-80-2 2-(acetylamino)phenol 

Downstream Products

• 151719-72-1 1-<3-(acetylamino)-4-(3-chloropropoxy)phenyl>ethanone 
• 1201079-07-3 1-(3-acetamido-4-ethoxyphenyl)ethanone 
• 1201079-10-8 1-(5-acetamido-4-ethoxy-2-nitrophenyl)ethanone 
• 1201080-09-2 N-(3-cyano-7-ethoxy-4-oxo-1,4-dihydroquinolin-6-yl)acetamide 
• 848133-76-6 7-ethoxy-6-acetylamino-4-chloro-quinoline-3-carbonitrile 
• 54255-50-4 3-amino-4-hydroxyacetophenone 

Relevant academic research and scientific papers

New heterocyclic chalcones. Part 6. Synthesis and cytotoxic activities of 5- or 6-(3-aryl- 2-propenoyl)-2(3H)-benzoxazolones

A number of chalcones bearing an oxazole cycle were synthesized by Claisen-Schmidt condensation of 5-acetyl-2(3 H )-benzoxazolone or 6-acetyl-2(3 H )-benzoxazolone and the appropriate aldehydes. The chalcones were evaluated for cytotoxic activity against several tumor cell lines - BV-173 (human B cell precursor leukemia), MCF-7 and MDA-MB-231 (human breast adenocarcinoma) using the MTT-dye reduction assay. The tested compounds exhibit concentration- dependent cytotoxic effects at micromolar concentrations. Exposure of the BV-173 tumor cell line to compound 3f results in strong monoand oligonucleosomal fragmentation of genomic DNA, as evidenced by a 'cell death detection' ELISA kit, which unambiguously indicates that the induction of apoptosis is implicated in the cytotoxic mode of action of the tested compound.

Fibrinogen receptor antagonists and their use

This invention relates to novel fused bicyclic compounds of the general formula (I): wherein the symbols are defined herein, to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and to methods of using the compounds, alone or in combination with other therapeutic agents. The compounds are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, and are therefore useful for the inhibition of platelet aggregation, and for the treatment of thrombotic diseases and other diseases.

NOVEL CARBAPENEM COMPOUND

A carbapenem compound represented by a following formula [1], wherein R1 is C1 to C3 alkyl or C1 to C3 alkyl substituted by hydroxy. R is hydrogen atom or a group which regenerates a carboxyl group by

FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE

This invention relates to novel fused bicyclic compounds of the general formula (I): wherein the symbols are defined herein, to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and to methods of using the compounds, alone or in combination with other therapeutic agents. The compounds are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, and are therefore useful for the inhibition of platelet aggregation, and for the treatment of thrombotic diseases and other diseases.

Novel compounds

The invention provides compounds of general formula (I) wherein Q, R, R2, R4, R5, R6, R7 and R8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Unequivocal Preparation of 4- and 5-Acyl-2-aminophenols

Unequivocal methods for the specific preparation of 4- or 5-acyl-2-aminophenols are reported. 5-Acyl-2-aminophenols are obtained by ring opening with dilute sodium hydroxide of 2(3H)-benzoxazolinones acylated at position 6. 4-Acyl-2-aminophenols are obtai